Previous 10 | Next 10 |
- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSEȁ...
2023-12-14 14:26:24 ET More on AbbVie, AstraZeneca, etc. GSK - Greenshoots In The Horizon AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AbbVie, Amgen among firms targeted for latest Medi...
2023-12-09 22:23:45 ET Summary Amneal Pharmaceuticals' stock price has been on a strong bull run, now exceeding $5 per share, and up over >145% this year. The company experienced losses in 2018 and 2019 but has since seen improvements in revenues and net income, as the manageme...
ONGENTYS ® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s Disease Complements Amneal’s existing Parkinson’s franchise and further expands specialty portfolio Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”...
2023-12-01 13:40:47 ET More on Amarin, Amneal, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript ...
- Partnering with Strides to commercialize recently U.S. FDA approved product - Represents another new product launch for Amneal in 2023 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (ȁ...
2023-11-07 15:19:08 ET Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Conference Call November 07, 2023 08:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief Executive Officer Chintu Patel - Co-Fou...
2023-11-07 12:53:17 ET More on AbbVie, GSK, etc. Arexvy Puts GSK Back On The Growth Prescription (Rating Upgrade) GSK plc (GSK) Q3 2023 Earnings Call Transcript GSK plc 2023 Q3 - Results - Earnings Call Presentation J&J’s patent win against Viatris...
2023-11-07 06:04:37 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal Pharmaceuticals raises its FY outlook Amneal to reorganize and simplify corporate structure Seeking Alpha’s Quant Rating on Amn...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...
The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of it...
Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to expand access Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” o...